Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04825535 Suspended - Clinical trials for Major Depressive Disorder

Non-Inferiority RCT Comparing Online and On-Site CBT in MDDi

Start date: April 2024
Phase: N/A
Study type: Interventional

In recent years, Cognitive Behavioral Therapy has been integrated with mindfulness meditation (CBT-M) following evidence for increased efficacy when modalities are combined. We will assess whether online group CBT-M plus standard psychiatric care is non-inferior in efficacy and more cost-effective than office-based, on-site group CBT-M (plus standard psychiatric care) per outcomes at post-intervention and at 6-month follow up in adults with major depressive disorder (MDD). This non-inferiority randomized controlled trial will employ both assessor-blinded and self-report outcome measures and will include a full economic evaluation.

NCT ID: NCT04311619 Suspended - Clinical trials for Major Depressive Disorder

Does rTMS Induce Synaptic Plasticity?

Start date: December 1, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to investigate the effect of repetitive transcranial magnetic stimulation (rTMS) on synaptic plasticity. UCB-J has been validated as a marker for synaptic density. We will use this tracer to examine if rTMS leads to changes in synaptic plasticity, specifically changes in synaptic density, in individuals receiving rTMS for MDD. If rTMS is proven effective for increasing synaptic plasticity, there is a significant potential of a new applicable treatment for a variety of diseases that affect brain physiology.

NCT ID: NCT03787290 Suspended - Clinical trials for Major Depressive Disorder

Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder

Start date: December 1, 2025
Phase: Phase 2
Study type: Interventional

Overall, the objective of this pilot study is to utilize the IL-6 receptor antagonist tocilizumab to prospectively evaluate the role of IL-6 in the antidepressant and immunological effects of whole body hyperthermia (WBH). The study seeks to replicate findings thus far that WBH has an antidepressant effect by administering the intervention at a site not involved in studies to date. Moreover, the current proposal may help the investigators better understand the role of IL-6 in the pathogenesis and treatment of depression which might point to novel immune-based interventions for Major Depressive Disorder (MDD). Finally, the current proposal holds promise for better understanding of a novel treatment for MDD, which is among the leading causes of health-related disability in the world.